INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy
Conditions: Breast Cancer; Breast Cancer Female; Breast Carcinoma Interventions: Behavioral: Endocrine Therapy Education Program Sponsors: Dana-Farber Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
Conditions: Breast Cancer Interventions: Drug: Trastuzumab deruxtecan (T-DXd) with pyrotinib Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Conditions: Triple Negative Breast Cancer Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Pembrolizumab; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Olaparib; Drug: Capecitabine Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Conditions: Metastatic Breast Cancer; Breast Cancer; Breast Cancer Stage IV; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Metastatic Triple-Negative Breast Carcinoma; Locally Advanced Breast Cancer; Locally Advanced Triple-Negative Breast Carcinoma Interventions: Drug: Pembrolizumab; Device: Cryoablation Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer
Conditions: Breast Cancer Interventions: Diagnostic Test: Brain imaging; Diagnostic Test: Analysis of circulating tumor DNA; Behavioral: Testing Morbidities Index Sponsors: Sunnybrook Health Sciences Centre; Princess Margaret Hospital, Canada; MOUNT SINAI HOSPITAL; Trillium Health Partners Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Seroma Formation After Modified Radical Mastectomy With Flap Fixation Technique in Breast Cancer Patients
Conditions: Breast-cancer Interventions: Procedure: Flap fixation technique Sponsors: Nakhon Phanom Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials
Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer: Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase Inhibitors(CDK4/6) as First Line Treatment. CYCLHER Study
Conditions: Advanced Breast Carcinoma Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials
The Effect of Training Given by Whatsapp Application on Mamography Health Beliefs and Behaviors
Conditions: Breast Cancer Sponsors: Kemal Yaran Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Conditions: Biliary Tract Cancer; Breast Cancer; Cervical Cancer; Colon Cancer; Endometrial Cancer; Esophageal Cancer; Gastric Cancer; GastroEsophageal Cancer; Head and Neck Cancer; Hepatocellular Cancer; Non-small Cell Lung Cancer; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Renal Cancer; Thyroid Cancer Interventions: Drug: MDX2001 Sponsors: ModeX Therapeutics, An OPKO Health Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
SG and Zimberelimab w/SRS in the Management of Metastatic Triple Negative BCBM
Conditions: Breast Cancer; Triple Negative Breast Cancer Interventions: Radiation: Stereotactic Radiation; Drug: Zimberelimab; Drug: Sacituzumab govitecan Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
BC Risk Assessment Before Top Surgery
Conditions: Breast Cancer; Risk Reduction Interventions: Diagnostic Test: Breast Cancer Risk Assessment Sponsors: Medical College of Wisconsin Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Breast Cancer Receiving Chemotherapy
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8 Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Conditions: Advanced Cancer; Breast Cancer Interventions: Drug: OKI-219; Drug: Fulvestrant; Drug: Trastuzumab Sponsors: OnKure, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study
Conditions: Breast Cancer Interventions: Other: data collection Sponsors: Regina Elena Cancer Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Conditions: Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Pancreatic Cancer; Ovarian Cancer; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Renal Pelvis Cancer; Bladder Cancer Interventions: Drug: LY4101174 Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
